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OBJECTIVE— Type 2 diabetes increases risk of stroke, perhaps because of impaired cere-
brovascular basal nitric oxide (NO) activity. We investigated whether this activity is improved by
a 2-week course of the xanthine oxidase inhibitor allopurinol.
RESEARCHDESIGNANDMETHODS— We performed a randomized, double-blind,
placebo-controlled crossover study. We measured the response to infusion of NG-monomethyl-
L-arginine (L-NMMA) in males with type 2 diabetes before and after allopurinol or placebo. The
primary end point was the change in internal carotid artery flow following L-NMMA infusion,
expressed as the area under the flow-per-time curve.
RESULTS— We enrolled 14 participants. Allopurinol improved responses to L-NMMA when
compared with responses associated with placebo (P  0.032; median reduction in internal
carotid artery flow following L-NMMA of 3,144 ml [95% CI 375–7,143]).
CONCLUSIONS— Xanthine oxidase inhibition with allopurinol appears to improve cere-
bral NO bioavailability, as evidenced by a greater response to infusion of L-NMMA.
Diabetes Care 32:135–137, 2009
T ype 2 diabetes conveys an increasedrisk of stroke (1,2), perhaps becauseof impaired cerebrovascular basal
nitric oxide (NO) bioavailability—a hy-
pothesis suggested by impaired response
to infusion of the endothelial NO syn-
thase inhibitor NG-monomethyl-L-
arginine (L-NMMA) (3). We performed a
randomized, double-blind, placebo-
controlled crossover study to test whether
this response is improved following a
course of the xanthine oxidase inhibitor
allopurinol.
RESEARCH DESIGN AND
METHODS— The study was ap-
proved by the West Medical research eth-
ics. Male patients aged 40 years with
type 2 diabetes of duration 5 years and
A1C9.0% were studied. Those with se-
vere extracranial internal carotid artery
(ICA) stenosis, known as coronary arterial
disease, and those receiving insulin were
excluded. All gave written informed con-
sent and underwent exercise tolerance
testing (ETT) to exclude subclinical coro-
nary arterial disease.
Baseline assessment of ICA flow and
middle cerebral artery mean flow velocity
was performed. Peripheral (radial) pulse-
wave analysis (PWA) and (carotid-radial)
pulse-wave velocity (PWV) were mea-
sured. Blood was drawn for measurement
of routine parameters and vascular endo-
thelial growth factor, soluble intercellular
adhesion molecules, E-selectin, and C-re-
active protein levels. Thereafter, a 45-ml
infusion of 0.8 mol  kg1  min1 clin-
ical-grade L-NMMA (Clinalfa/Bachem-
Ag, Weil-am-Rhein, Germany) dissolved
in normal saline was given intravenously
over 15 min. ICA, middle cerebral artery,
PWA, and PWV parameters were re-
peated upon cessation of infusion and 10,
20, and 30 min thereafter.
Participants were then randomized to
either 300 mg allopurinol or a matching
placebo, each taken orally once daily for 2
weeks. Following this, all assessments
were repeated. A 2-week washout period
then ensued, after which repeat assess-
ment, a 2-week dose of the other agent
(placebo or allopurinol), and the final as-
sessment occurred.
The primary end point was change in
ICA flow induced by the L-NMMA infu-
sion and expressed as area under the flow-
per-time curve (AUC) measured from the
start of infusion to 20 min after its com-
pletion (3,4). A negative AUC signifies the
expected reduction in ICA flow following
L-NMMA infusion. Based on our previous
pilot data (3), a sample of 20 patients
would enable detection of a clinically sig-
nificant improvement in L-NMMA re-
sponsiveness following allopurinol (to
75% of that seen in nondiabetic indi-
viduals) with 90% power (a´  5%). Sec-
ondary end points were change in
augmentation index (measured during
PWA), PWV, and blood markers.
Standard crossover study analysis
techniques were employed, and differ-
ences between the study periods were
compared using paired nonparametric
tests (Wilcoxon’s signed-rank test). A
positive difference between study periods
represents improvement in favor of allo-
purinol. A mixed-effects model was gen-
erated to adjust for any effect of treatment
ordering.
RESULTS— Fourteen patients were
recruited. Ten completed the protocol;
one had a positive ETT, two failed to at-
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tend after the ETT and the first visit, and
one was unable to receive L-NMMA dur-
ing his last study visit. The study was ter-
minated early as a result of the national
lack of availability of L-NMMA. No ad-
verse events occurred.
Of those recruited, mean SD age was
53.1  10.8 years, 85.7% (n  12) had
coexisting hypertension, 78.6% (n  11)
were receiving oral hypoglycemic agents,
78.6% were receiving ACE inhibitor or an-
giotensin receptor blocker therapy, 64.3%
were receiving antiplatelet therapy, and
92.3% were on lipid-lowering therapy.
Mean A1C was 6.6 0.94%.
The baseline response to L-NMMA in-
fusion was impaired. ICA flow fell by a
median of 4.8% (95% CI 17.3 to 9.4;
P  0.25). We saw no change in blood
pressure parameters where AUCs were
considered or in the augmentation index
or PWV following L-NMMA (Table 1 ).
Allopurinol treatment significantly
augmented the reduction in ICA flow fol-
lowing L-NMMA infusion (Table 1). ICA
flow fell by a median of 11.9% (95% CI
2.5 to 23.3;P0.04) following L-NMMA
after treatment with allopurinol. The
mixed-effects model revealed results con-
sistent with the main analysis (P0.046 for
allopurinol vs. placebo) and found no sig-
nificant order effect (P 0.51). Allopurinol
led to an improvement in response to L-
NMMA in 8 of the 10 individuals.
The preinfusion augmentation index,
PWV (Table 1), and L-NMMA (data not
shown) did not differ significantly be-
tween the treatment periods (Table 1). No
significant differences were seen in any of
the blood markers (Table 1).
CONCLUSIONS— L -NMMA re -
duces cerebral blood flow through restric-
tion of NO activity. The higher the basal
NO activity, the larger the effect. Treat-
ment with allopurinol enhanced this ef-
fect, implying that allopurinol improves
basal levels of NO activity, causing them
to approach those previously seen in
healthy volunteers (3).
We saw no improvement in blood
markers or measures of peripheral arte-
rial stiffness. These results contrast with
a previous study where forearm blood
flow responses were improved follow-
ing allopurinol (5), but we employed
different techniques and did not design
our study to detect differences in these
parameters. Interestingly, at the base-
line visit, we failed to replicate the in-
crease in the augmentation index or
PWV following L-NMMA seen previ-
ously in healthy volunteers (6), and it
may be that this response is also im-
paired in those with diabetes.
The potential beneficial effects of
allopurinol on the vasculature are two-
fold: it reduces xanthine oxidase–
mediated O2
 production (7) and
reduces serum uric acid (8). Previous
studies have shown a beneficial effect of
xanthine oxidase inhibition on mea-
sures of forearm or coronary endothelial
function (9), but this is the first human
study to show improvement in cerebro-
vascular function.
We followed a rigorous protocol, and
improvements in peripheral vascular re-
sponses to L-NMMA have been shown
following treatment with other cardio-
vasculature-protective agents (10,11).
However, we studied fewer patients
than intended because of the lack of on-
going availability of L-NMMA, which re-
duces our statistical power, but the
consistency of effect we saw is reassur-
ing. Our dosing period was short, and
we cannot exclude the possibility that
the changes we saw may subsequently
be reversed by other sources of O2
.
Also, we have only examined the effect
on endothelial NO synthase activity,
and other forms of NO and O2
 pro-
duction may be important.
In summary, our data show that xan-
thine oxidase inhibition with allopurinol
improves cerebral NO activity, which
may benefit cerebrovascular health. We
encourage further investigation of its use
for stroke prevention.
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